These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 29791318)

  • 1. The inhibitors - a challenge for the management of patients with hereditary haemophilia A.
    Mihăilă RG
    Rom J Intern Med; 2018 Sep; 56(3):143-152. PubMed ID: 29791318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies.
    Volkers P; Hanschmann KM; Calvez T; Chambost H; Collins PW; Demiguel V; Hart DP; Hay CRM; Goudemand J; Ljung R; Palmer BP; Santagostino E; van Hardeveld EM; van den Berg M; Keller-Stanislawski B
    Haemophilia; 2019 May; 25(3):398-407. PubMed ID: 31066174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent but low titre factor VIII inhibitors in haemophilia A patients treated with high purity concentrates.
    Zanon E; Zerbinati P; Girolami B; Bertomoro A; Girolami A
    Blood Coagul Fibrinolysis; 1999 Apr; 10(3):117-20. PubMed ID: 10357004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates.
    Scharrer I; Bray GL; Neutzling O
    Haemophilia; 1999 May; 5(3):145-54. PubMed ID: 10444280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity.
    Oldenburg J; Lacroix-Desmazes S; Lillicrap D
    Haematologica; 2015 Feb; 100(2):149-56. PubMed ID: 25638804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better.
    Franchini M
    Blood Transfus; 2010 Oct; 8(4):292-6. PubMed ID: 20967172
    [No Abstract]   [Full Text] [Related]  

  • 8. Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better.
    Mannucci PM
    Blood Transfus; 2010 Oct; 8(4):288-91. PubMed ID: 20967171
    [No Abstract]   [Full Text] [Related]  

  • 9. Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.
    Dargaud Y; Pavlova A; Lacroix-Desmazes S; Fischer K; Soucie M; Claeyssens S; Scott DW; d'Oiron R; Lavigne-Lissalde G; Kenet G; Escuriola Ettingshausen C; Borel-Derlon A; Lambert T; Pasta G; Négrier C
    Haemophilia; 2016 Jan; 22 Suppl 1(Suppl 1):1-24. PubMed ID: 26728503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor VIII--Baxter: rAHF-PFM, recombinant anti-haemophilic factor--protein-free method, recombinant factor VIII--protein-free.
    Drugs R D; 2003; 4(6):366-8. PubMed ID: 14584967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma-derived versus recombinant factor concentrates in PUPs: a never ending debate?
    Berntorp E
    Hamostaseologie; 2017 Jan; 37(1):53-57. PubMed ID: 27878207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of inhibitor development in hemophilia A in 2016. A glimpse into the future?
    Franchini M; Lippi G
    Thromb Res; 2016 Dec; 148():96-100. PubMed ID: 27816852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.
    Gouw SC; van der Bom JG; Auerswald G; Ettinghausen CE; Tedgård U; van den Berg HM
    Blood; 2007 Jun; 109(11):4693-7. PubMed ID: 17218379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemophilia. Strategies for the treatment of inhibitor patients.
    Ingerslev J
    Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.
    Peyvandi F; Mannucci PM; Garagiola I; El-Beshlawy A; Elalfy M; Ramanan V; Eshghi P; Hanagavadi S; Varadarajan R; Karimi M; Manglani MV; Ross C; Young G; Seth T; Apte S; Nayak DM; Santagostino E; Mancuso ME; Sandoval Gonzalez AC; Mahlangu JN; Bonanad Boix S; Cerqueira M; Ewing NP; Male C; Owaidah T; Soto Arellano V; Kobrinsky NL; Majumdar S; Perez Garrido R; Sachdeva A; Simpson M; Thomas M; Zanon E; Antmen B; Kavakli K; Manco-Johnson MJ; Martinez M; Marzouka E; Mazzucconi MG; Neme D; Palomo Bravo A; Paredes Aguilera R; Prezotti A; Schmitt K; Wicklund BM; Zulfikar B; Rosendaal FR
    N Engl J Med; 2016 May; 374(21):2054-64. PubMed ID: 27223147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Porcine recombinant factor VIII: an additional weapon to handle anti-factor VIII antibodies.
    Mannucci PM; Franchini M
    Blood Transfus; 2017 Jul; 15(4):365-368. PubMed ID: 27483484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-reactivity to porcine factor VIII of factor VIII inhibitors in patients with haemophilia in Australia and New Zealand.
    Lloyd JV; Street AM; Berry E; McPherson J; Ekert H; Lammi A; McWhirter WR; Duncan EM; Maxwell EL; Rowell J; Baker RI; Leahy MF; Jupe D
    Aust N Z J Med; 1997 Dec; 27(6):658-64. PubMed ID: 9483232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of factor VIII inhibitors.
    Acharya SS; DiMichele DM
    Best Pract Res Clin Haematol; 2006; 19(1):51-66. PubMed ID: 16377541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of agents that by-pass factor VIII inhibitors in patients with haemophilia.
    Roberts HR
    Vox Sang; 1999; 77 Suppl 1():38-41. PubMed ID: 10529686
    [No Abstract]   [Full Text] [Related]  

  • 20. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation.
    Hay CR; Ludlam CA; Colvin BT; Hill FG; Preston FE; Wasseem N; Bagnall R; Peake IR; Berntorp E; Mauser Bunschoten EP; Fijnvandraat K; Kasper CK; White G; Santagostino E
    Thromb Haemost; 1998 Apr; 79(4):762-6. PubMed ID: 9569189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.